Preclinical efficacy and safety of mepolizumab (SB-240563), a humanized monoclonal antibody to IL-5, in cynomolgus monkeys.

@article{Hart2001PreclinicalEA,
  title={Preclinical efficacy and safety of mepolizumab (SB-240563), a humanized monoclonal antibody to IL-5, in cynomolgus monkeys.},
  author={Timothy K. Hart and R. M. Cook and Parnian Zia-Amirhosseini and Elisabeth A. Minthorn and Teresa S. Sellers and Beverly E. Maleeff and Susie Eustis and Lester W. Schwartz and Paulus Tsui and Edward R. Appelbaum and Elise Martin and Peter J. Bugelski and Danuta J. Herzyk},
  journal={The Journal of allergy and clinical immunology},
  year={2001},
  volume={108 2},
  pages={250-7}
}
BACKGROUND Allergic respiratory diseases are characterized by large numbers of eosinophils and their reactive products in airways and blood; these are believed to be involved in progressive airway damage and remodeling. IL-5 is the principal cytokine for eosinophil maturation, differentiation, and survival. Mepolizumab (SB-240563), a humanized monoclonal antibody (mAb) specific for human IL-5, is currently in clinical trials for treatment of asthma. OBJECTIVE The purpose of this study was to… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 48 extracted citations

Impact of reslizumab on outcomes of severe asthmatic patients: current perspectives

Patient related outcome measures • 2018
View 2 Excerpts
Highly Influenced

Biomarkers for severe eosinophilic asthma.

The Journal of allergy and clinical immunology • 2017

Similar Papers

Loading similar papers…